[Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia].

Abstract

OBJECTIVE:

To analyze the clinical efficacy of imatinib mesylate (IM) for Ph-positive or BCR-ABL positive chronic myeloid leukemia (CML) to couple the trough plasma concentrations (C mins) of IM with clinical responses and adverse events (AEs).

METHODS:

One hundred and one CML patients received IM therapy, and Cmins of IM were determined in 30 patients.

RESULTS:

(1) Cumulative complete hematological response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR) and negative BCR/ABL fusion gene rates were 96.6%, 86.5%, 77.5% and 47.2%, respectively, in CML-CP patients. In accelerated and blastic phases (AP and BC) patients, CHR, MCyR, CCyR and negative BCR-ABL fusion gene rates were 58.3%, 25.0%, 25.0%, 8.3%, respectively. (2) Mean Cmins of IM was significantly higher in the CCyR at 1 year [(1472 +/- 482) microg/L] group than in the non-CCyR at 1 years group [(1067 +/- 373) microg/L] (P < 0.05), and higher in the MMR at 1 year group than in the non-MMR at 1 years group [(1624 +/- 468) microg/L vs (1137 +/- 404) microg/L, P < 0.05].

CONCLUSION:

IM significantly improves cytogenetic and molecular response, event-free survival, and overall survival for patients with Ph-positive CML. The Cmins of IM exerts a significant impact on clinical response (CCyR and MMR at 1 year).

• Authors: Chen Chen, Wen Wang, Cong-Gao Xu, Ming Hou, Lu-Qun Wang, Chuan-Fang Liu, Qiang Song, Chun-Yan Ji
• Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (Zhonghua Xue Ye Xue Za Zhi) Vol. 32 Issue 7 Pg. 450-3 (Jul 2011) ISSN: 0253-2727 [Print] China
• PMID: 22213863 (Publication Type: Clinical Trial, English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Benzamides
• Piperazines
• Pyrimidines
• Imatinib Mesylate

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Agents (blood, therapeutic use)
• Benzamides
• Female
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (blood, drug therapy)
• Male
• Middle Aged
• Piperazines (blood, therapeutic use)
• Pyrimidines (blood, therapeutic use)
• Treatment Outcome
• Young Adult